Status:
COMPLETED
Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer
Lead Sponsor:
Alberta Health services
Collaborating Sponsors:
Calgary Health Region
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the mor...
Detailed Description
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the mor...
Eligibility Criteria
Inclusion
- Stage T1 and T2 prostate cancer
- Prostate specific antigen (PSA)\>=20 and Gleason score\<=6
- PSA\<=15 and Gleason score 7
- Signed informed consent
Exclusion
- No hip prosthesis, pins or screws
- No previous pelvic radiotherapy
- No inflammatory bowel disease
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00126165
Start Date
September 1 2004
End Date
August 1 2011
Last Update
January 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2